CONCLUSIONS	If confirmed by further investigations , the results of this pilot study suggest that iloprost , infused for both brief and long periods , is able to reduce the cardiovascular risk factor PAI-1 , increases free walking capacity and does not affect glucometabolic control and blood pressure in type-2 diabetic patients complicated by macroangiopathy .\